A New Marker For Cancer Prognosis?
Dr M Izquierdo from the University Hospital in Amsterdam, the Netherlands, reported on a possible new marker, called LRP protein, for chemotherapy resistance not mediated by P-glycoprotein and disease prognosis.
Dr Izquierdo said that in 66 patients with ovarian carcinoma treated with chemotherapy, LRP was detected in 74% of patients and PGP in 13%. Of the responders, 50% were LRP-negative compared to only 8% of those who were LRP-positive. Also, LRP-positive patients had a shorter progression-free period than LRP- negative patients. Therefore, said Dr Izquierdo, LRP appears to define a drug- resistant phenotype and has a significant correlation with a negative prognosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze